Skip to content

Remazolam inhibits 95% effective dose of tracheal intubation cardiovascular response in frail and non-frail elderly adults

Remazolam inhibits 95% effective dose of tracheal intubation cardiovascular response in frail and non-frail elderly adults

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200055709
Enrollment
Unknown
Registered
2022-01-16
Start date
2022-01-15
Completion date
Unknown
Last updated
2023-06-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

lumbar spondylolisthesis,lumbar rapture

Interventions

Nonfrailty group and frailty group:According to the cardiovascular response of the previous patient with endotracheal intubation, each group determined the dose of remimazolam for the next patient acc

Sponsors

Xianghu Hospital, The First Affiliated Hospital of Nanchang University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. ASA I or II; 2. Elective surgery; 3. Aged over 65 years; 4. BMI: 20-25 kg/m^2; 5. Patients undergoing single-chamber endotracheal catheter implantation under general anesthesia; 6. Informed consent signed by patient or authorized person; 7. No hypertension or grade I hypertension.

Exclusion criteria

Exclusion criteria: 1. SBP >= 160 mmHg, DBP >= 110 mmHg, HR 110 >= times/min; 2. Known difficult airway; 3. Serious cardiovascular and cerebrovascular diseases; 4. History of alcoholism; 5. History of drug allergy; 6. History of neurological disease or inability to communicate properly.

Design outcomes

Primary

MeasureTime frame
Endotracheal intubation response;EC95;

Secondary

MeasureTime frame
adverse effect;

Countries

China

Contacts

Public ContactCheng Liqin

The First Affiliated Hospital of Nanchang University

2235616728@qq.com+86 13968849974

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026